Frontline therapy with high-dose imatinib versus second generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia - a propensity score analysis (Q42391592)
Jump to navigation
Jump to search
scientific article published on 12 May 2016
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Frontline therapy with high-dose imatinib versus second generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia - a propensity score analysis |
scientific article published on 12 May 2016 |
Statements
1 reference
Frontline therapy with high-dose imatinib versus second generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia - a propensity score analysis (English)
1 reference
1 reference
Hagop Kantarjian
1 reference
William Wierda
1 reference
Farhad Ravandi
1 reference
Elias Jabbour
1 reference
Gautam Borthakur
1 reference
Sherry Pierce
1 reference
Guillermo Garcia-Manero
1 reference
Jorge E Cortes
1 reference
Marina Konopleva
1 reference
Koji Sasaki
1 reference
Naval Daver
1 reference
Koichi Takahashi
1 reference
Toshihisa Satta
1 reference
May Beth Rios
1 reference
12 May 2016
1 reference
1 reference
101
1 reference
e324-7
1 reference
Identifiers
1 reference
1 reference
1 reference